Search - tctmd.com

Displaying 101 - 120 of 149

Sort: Relevancy | Date

News Industry News

Boston Scientific Receives U.S. FDA Approval For Resonate™ Family Of High-Voltage Devices

May 09, 2017

News Industry News

Abbott Announces CE Mark and First Use of the World's First Smartphone Compatible Insertable Cardiac Monitor

May 08, 2017

News Industry News

LivaNova Announces New Data Reaffirming Value of Perceval for Aortic Valve Replacement in Aortic Stenosis Patients

May 05, 2017

News Industry News

LivaNova Acquires Caisson Interventional, LLC

May 02, 2017

News Daily News

Updated PARTNER 2 Valve-in-Valve Registry: More Experience, Better Outcomes

Shelley Wood

May 02, 2017

News Daily News

TCTMD’s Top 10 Most Popular Stories for April 2017

Shelley Wood

April 28, 2017

News Daily News

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Michael O'Riordan

April 18, 2017

News Conference News

Mixed Results, With Some Promising Data, in Heart Failure Destination Therapy Trial

Todd Neale

April 07, 2017

News Daily News

Looking Beyond Randomized Trials: Could a Wider Range of Studies Support Device Approval?

Todd Neale

April 05, 2017

News Daily News

SCOUTing the ‘Forgotten Valve’: Promise for a New Percutaneous Treatment Option in Tricuspid Regurgitation

Yael L. Maxwell

April 04, 2017

News Features

Living or Leaving: Does Palliative Care Deserve a Place at the TAVR Table?

Caitlin E. Cox

March 31, 2017

News Daily News

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

Michael O'Riordan

March 29, 2017

News Conference News ACC 2017

MitraClip Commercial Experience at 1 Year Sheds Light on Progress and Lingering Concerns

L.A. McKeown

March 27, 2017

News Daily News

FDA: Class I Recall for Over 47,000 HeartStart MRx Monitor/Defibrillator Units

L.A. McKeown

March 24, 2017

News Conference News ACC 2017

Prioritizing Impella Support May Boost Cardiogenic Shock Survival, Pilot Study Suggests

Todd Neale

March 22, 2017

News Featured Fellow

Eric Secemsky, MD, MSc

Yael L. Maxwell

March 21, 2017

News Conference News ACC 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Michael O'Riordan

March 19, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Three

Shelley Wood

March 19, 2017

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

News Conference News ACC 2017

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Michael O'Riordan

March 18, 2017

Advertisement

Boston Scientific Receives U.S. FDA Approval For Resonate™ Family Of High-Voltage Devices

Abbott Announces CE Mark and First Use of the World's First Smartphone Compatible Insertable Cardiac Monitor

LivaNova Announces New Data Reaffirming Value of Perceval for Aortic Valve Replacement in Aortic Stenosis Patients

LivaNova Acquires Caisson Interventional, LLC

Updated PARTNER 2 Valve-in-Valve Registry: More Experience, Better Outcomes

TCTMD’s Top 10 Most Popular Stories for April 2017

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Mixed Results, With Some Promising Data, in Heart Failure Destination Therapy Trial

Looking Beyond Randomized Trials: Could a Wider Range of Studies Support Device Approval?

SCOUTing the ‘Forgotten Valve’: Promise for a New Percutaneous Treatment Option in Tricuspid Regurgitation

Living or Leaving: Does Palliative Care Deserve a Place at the TAVR Table?

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

MitraClip Commercial Experience at 1 Year Sheds Light on Progress and Lingering Concerns

FDA: Class I Recall for Over 47,000 HeartStart MRx Monitor/Defibrillator Units

Prioritizing Impella Support May Boost Cardiogenic Shock Survival, Pilot Study Suggests

Eric Secemsky, MD, MSc

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Live From Washington: ACC 2017, Day Three

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content